ClinicalTrials.gg
Not yet recruitingNCT07495033Updated Apr 9, 2026

Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease

A Phase 3 interventional study of Telitacicept and Placebo in CTD-ILD, sponsored by RemeGen Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Interstitial lung disease (ILD) is a common pulmonary manifestation in chronic tissue diseases (CTD), significantly affecting patient's prognosis.

The main purpose of this study is to evaluate the efficacy of telitacicept compared with placebo in slowing down the decline in lung volume in patients with interstitial lung disease associated with connective tissue disease (CTD-ILD) on the basis of standard treatment.

02

Conditions studied

  • CTD-ILD
03

In context

Lead sponsor

RemeGen Co., Ltd. is the lead sponsor of 83 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary provided;
  2. Male or female aged ≥ 18 years old;
  3. Documented diagnosis of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), Sjogren's syndrome (SjD) , Systemic sclerosis(SSc),or mixed connective tissue disease (MCTD) in accordance with internationally recognized classification criteria;
  4. Diagnosis of ILD on High Resolution Computed Tomography (HRCT) with disease extent of greater than or equal to (≥) 10% of the whole lung (WL-ILD);
  5. During screening, FVC%Pred ≥ 45%;
  6. During screening, DLCO%Pred(corrected for ) ≥ 30%;
  7. Stable standard treatment was received before randomization to control ILD and/or connective tissue disease;

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of Interstitial lung disease other than CTD-ILD;
  2. ILD progresses rapidly within 12 weeks before screening or during screening;
  3. During screening, HRCT showed severe emphysema (the degree of emphysema exceeded that of ILD);
  4. Obstructive pulmonary disease (pre-bronchodilator (FEV1) /FVC \<0.7);
  5. Pulmonary arterial hypertension requiring therapy, as determined by the investigator;
  6. Having diffuse alveolar hemorrhage (DAH) or other pulmonary conditions that may have confounding effects, as well as related signs or symptoms;
  7. Unable to complete the pulmonary function test, or requiring supplementary oxygen supply;
  8. laboratory abnormalities;
  9. prolongation on ;
  10. Allergy to human or mouse-derived biological products, or history of other drug allergies, and the investigator deems that the patient is not eligible to participate.
  11. Previous treatments received:

    • Previous or planned organ transplantation or bone marrow transplantation;
    • Plasma exchange or extracorporeal light separation exchange was performed within 6 months before randomization, or a plasma filtration device was used;
    • Any targeted BLyS or APRIL drug treatment was received within 12 weeks before randomization;
    • Biologic therapy was received within 12 weeks or within 5 half-lives of the corresponding drug (whichever is longer) before randomization;
    • B-cell depletion drugs were used within 6 months before randomization;
    • Non-biological systemic drugs other than standard treatment were used within 4 weeks before randomization;
    • Anti-fibrotic drugs were used within 4 weeks before randomization;
    • Cyclophosphamide treatment was received within 6 months before randomization;
    • Cytotoxic drugs were used within 6 months before randomization;
    • Intravenous or intramuscular were used within 4 weeks before randomization;
  12. Major surgery within 12 weeks prior to screening or planned during the duration of the study;
  13. Received or plan to receive any within 28 days prior to randomization;
  14. Participation in any clinical trial 28 days prior to randomization or within 5 times the half-life of an drug (whichever is longer);
  15. has active hepatitis or a history of severe liver disease;
  16. Acute or chronic infection requiring treatment;
  17. suffered from symptomatic herpes zoster within 12 weeks prior to screening;
  18. Active tuberculosis;
  19. infection;
  20. History of malignant tumors;
  21. Significant cardiovascular disease, liver, kidney, respiratory, endocrine or hematologic disease, or other medical conditions that, in the opinion of the investigator, would preclude the subject's participation in the study or require hospitalization during the trial;
  22. History of drug or alcohol abuse or dependence;
  23. Pregnant or lactating women, and those intending to become pregnant during the trial;
  24. Patients considered unsuitable by the investigator to participate in the trial ;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Telitacicept

    Participants will receive elitacicept in addition to standard therapy.

    Drug: Telitacicept

  • Placebo comparator
    Placebo

    Participants will receive placebo in addition to standard therapy.

    Drug: Placebo

Interventions

  • Subjects will receive Telitacicept.

  • DrugPlacebo

    The placebo contains no active ingredients. To maintain the blind, the placebo matches the active drug in all physical aspects.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in FVC(mL) at Week 52

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Change from Baseline in FVC%Pred at Week 52

    Time frame: Baseline and Week 52

  2. Change from Baseline in DLCO%Pred at Week 52

    Time frame: Baseline and Week 52

  3. Time to ILD Progression or Death

    Time frame: The time from Baseline to Week 52

  4. Change from Baseline in Quantitative Interstitial Lung Disease in the Whole Lung (QILD-WL) At Week 52

    Time frame: Baseline and Week 52

  5. Change from Baseline in Quantitative Measures of Lung Fibrosis (QLF) in the Whole Lung At Week 52

    Time frame: Baseline and Week 52

  6. the proportion of subjects with a QILD-WL score reduction ≥2% at week 52

    Time frame: Baseline and Week 52

  7. The proportion of subjects who showed a ≥5% decrease in FVC (mL) from baseline at week 52;

    Time frame: Baseline and Week 52

  8. The proportion of subjects who showed a ≥10% decrease in FVC (mL) from baseline at week 52;

    Time frame: Baseline and Week 52

  9. Change from Baseline in the short form health survey(SF-36) at Week 52

    Time frame: Baseline and Week 52

  10. Change from Baseline in Patient global impression of severity(PGI-S) at Week 52

    Time frame: Baseline and Week 52

  11. Changes from baseline in immunological markers(IgG、IgA、IgM、CD19+ B)at Week 52

    Time frame: Baseline and Week 52

  12. Incidence and severity of adverse events

    Time frame: From signing of informed consent until 4 weeks after the last dose.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for May 2029, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 27, 2026
StartEst.
Apr 20, 2026
Primary completionEst.
May 31, 2029
CompletionEst.
May 31, 2030
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07495033
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Apr 20, 2026 (estimated)
Primary completion
May 31, 2029 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Apr 9, 2026

Study contacts

Mengtao Li
Contact
Mengtao.li@cstar.org.cn
+86-10-69158354
Qian Wang
Contact
Zhengaqian@126.com
+86-10-69158354

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion